SNDX logo

SYNDAX PHARMACEUTICALS INC

SNDXNASDAQ
🏆 #2156 by market capUS Equity
$742.68▼ $21.09 (−2.84%)
Simulated price
🔔
Track SNDX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.8%
7d▲ 3982.9%
14d▲ 4003.2%
30d▲ 3699.8%
ytd▲ 3433.2%
1y▲ 4669.9%
🏦Market Cap
$1.61B
Small Cap
📈Revenue Growth (YoY)
+627.8%
High Growth
📊Gross Margin
97.5%
High
💵FCF Margin
-87.6%
Thin
⚖️P/S Ratio
6.4x
Fair
Otter Score
60
Fair

Trading Snapshot

Day Range
$738.85 – $748.75
52-Week Range
$12.99 – $25.59
Volume
$2.73B
Avg Volume
$2.21B
Shares Outstanding
88.6M
Next Earnings
Dec 5, 2026

Fundamentals Snapshot

Annual Revenue
$172M
Last Q Revenue
$73M
P/E Ratio
-7.2
P/S Ratio
6.4x
EPS (TTM)
$-2.48
Dividend Yield
0.00%
Dilution (1yr)
+1.0%

Why Investors Own SNDX

  • ✓High-growth profile — revenue up +28.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 43% gross margin and 17% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SNDX logo

SYNDAX PHARMACEUTICALS INC

SNDX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$172M▲ +627.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
96.0%▼ −0.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$273M▼ −19.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$323M▲ +17.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
86.6M▲ +1.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$212M▼ −$20M YoY
StockOtter · stockotter.space

About SYNDAX PHARMACEUTICALS INC

Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$794.53
▲ +7.0% Upside
High Target$916.07
Low Target$634.16
Based on 15 analysts

Latest News & Updates

🚀
Barron’s·2h ago

SYNDAX PHARMACEUTICALS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift SNDX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

SYNDAX PHARMACEUTICALS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.